<!DOCTYPE html>
<html lang="en-US">
<!--********************************************-->
<!--*       Generated from PreTeXt source      *-->
<!--*       on 2022-07-30T11:18:37+02:00       *-->
<!--*   A recent stable commit (2020-08-09):   *-->
<!--* 98f21740783f166a773df4dc83cab5293ab63a4a *-->
<!--*                                          *-->
<!--*         https://pretextbook.org          *-->
<!--*                                          *-->
<!--********************************************-->
<head>
<meta http-equiv="Content-Type" content="text/html; charset=UTF-8">
<meta name="robots" content="noindex, nofollow">
</head>
<body class="ignore-math">
<h5 class="heading"><span class="type">Paragraph</span></h5>
<p>Atovaquone/proguanil, sold under the trade names Malarone among others, is a combination of two antimalarial medication atovaquone and proguanil. It is used to treat and prevent malaria, including chloroquine-resistant malaria.  A standard adult pill of Malarone contains 250mg of atovaquone and 100mg of proguanil. A typical dose is one pill taken at the same time each day. An individual must maintain at least 300mg of atovaquone and 30mg of proguanil in their blood at all times in order to prevent contracting malaria. A typical adult eliminates atovaquone at a rate that corresponds to a half-life (time to eliminate one half of the original dose) of 48 hours. The half-life of proguanil is 12 hours.<a href="" class="fn-knowl original" data-knowl="./knowl/fn-21-hidden.html" title="Footnote 1.8.5"><sup> 5 </sup></a></p>
<span class="incontext"><a href="firstlook08.html#p-608" class="internal">in-context</a></span>
</body>
</html>
